Development, characterization and biological in vitro assays of paclitaxel-loaded PCL polymeric nanoparticles

Publication date: Available online 24 November 2018Source: Materials Science and Engineering: CAuthor(s): Juliana Palma Abriata, Roger Casanova Turatti, Marcela Tavares Luiz, Giovanni Loureiro Raspantini, Larissa Bueno Tofani, Robson Luis Ferraz do Amaral, Kamilla Swiech, Priscyla Daniely Marcato, Juliana Maldonado MarchettiAbstractAdenocarcinoma is the most lethal gynecologic tumor and treatment usually consists in surgery followed by chemotherapy. However, the chemotherapy benefits are eventually limited due to drug toxicity to normal tissues and cells, which cause several and harsh side effects. Paclitaxel (PCX) is the drug of first choice for ovarian cancer treatment, but it has low aqueous solubility, which reduces its bioavailability. Thus, in the commercial drug, Taxol®, PCX is solubilized in a mixture of toxic surfactants. The development of drug nanocarriers has been investigated to promote the reduction of toxic effects and increase the safety and therapeutic efficacy of PCX. The aim of this work was the development and characterization of PCX loaded nanoparticles (PNPCX) and evaluation of in vitro efficacy of developed system using adenocarcinoma cell line. The nanocarrier was successfully obtained using nanoprecipitation technique. The results showed that the PNPCX-A had a particle size distribution around 140 nm and polydispersity index smaller than 0.1, with high PCX encapsulation efficiency. The results obtained were suitable for the intravenous administrati...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research